Stephen KL Chia
机构: Medical Oncology, British Columbia Cancer Agency
每年引用次数
引用次数
引用: 31,786
H-指数: 78
I10-指数 : 208
出版物: 538
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan , Suzette Delaloge , Frankie A Holmes , Beverly Moy
Lancet Oncology 17 ( 3) 367 -377
646
2016
A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198.
Stephen KL Chia , Susan Ellard , Mihaela Mates , Stephen Welch
Journal of Clinical Oncology 31 518 -518
1
2013
Whole transcriptome sequencing in metastatic cancer: A review of expression outliers in 113 metastatic breast cancer patients.
Nathalie LeVasseur , Veronika Csizmok , Melika Bonakdar , Yaoqing Shen
Journal of Clinical Oncology 37 3080 -3080
1
2019
Whole genome sequencing in metastatic breast cancer: Lessons learned from the BC Cancer personalized oncogenomics program.
Nathalie LeVasseur , Yaoqing Shen , Eric Yang Zhao , Sophie Sun
Journal of Clinical Oncology 36 ( 15_suppl) 12065 -12065
1
2018
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
Stephen KL Chia , Philippe L Bedard , John Hilton , Eitan Amir
Journal of Clinical Oncology 36 1029 -1029
13
2018
Ribociclib (RIB) plus fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
Dennis J Slamon , Patrick Neven , Stephen KL Chia , Seock-Ah Im
Journal Of Clinical Oncology 36 ( 15)
2018
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Arlene Chan , Suzette Delaloge , Frankie A Holmes , Beverly Moy
Lancet Oncology 17 ( 3) 367 -377
539
2016
On-treatment (tx) dynamic circulating tumor DNA changes (ΔctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER22 advanced breast cancer (ABC) in MONALEESA-3 (ML-3)
Stephen KL Chia , Nadia Solovieff , Mukta Joshi , Seock-Ah Im
Journal of Clinical Oncology 42 ( 16)
2024
http://jnci. oxfordjournals. org
TORSTEN O NIELSEN , MAGGIE CU CHEANG , STEPHEN K CHIA , DAVID VODUC
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Commentary
S CHIA , C BRYCE , K GELMON
Lancet (British edition) 365 ( 9472) 1665 -1666
6
2005
THE FACES OF MODERN-ART
A LINKE , V ACCONCI , M BARNEY , G BASELITZ
DU-DIE ZEITSCHRIFT DER KULTUR ( 1) 14 -&
1994
Effect of Community Population Size on Breast Cancer Screening, Stage Distribution, Treatment Use and Outcomes
Chris Bajdik , Ivo A. Olivotto , Caroline Speers , Scott Tyldesley
Canadian Journal of Public Health-revue Canadienne De Sante Publique 103 ( 1) 46 -52
26
2012
The development of a standardized software platform to support provincial population-based cancer outcomes units for multiple tumour sites: OaSIS - Outcomes and Surveillance Integration System.
Jonn Wu , Cheryl Ho , Janessa Laskin , David Gavin
Studies in health technology and informatics 183 98 -103
3
2013
Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?
Sheina A Macadam , Rona E Cheifetz , Stephen Chia , Karen Slater
Current Oncology 28 ( 1) 702 -715
2021
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies.
Stephen Johnston , Judith M. Bliss , Angelo Di Leo , Ian Bradbury
NPJ breast cancer 7 ( 1) 1 -12
2021
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Funda Meric-Bernstam , Kathy S Albain , Suzette Delaloge , Gabriel Hortobagyi
Cancer Research 81
48
2021
Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
José A García-Sáenz , Cristina Saura , Lisa D Eli , Mark E Burkard
Cancer Research 81
2021
Abstract PD2-07: Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
Eva Ciruelos , Dejan Juric , Pamela Drullinsky , Nicholas Turner
Cancer Research 81
2021
Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial
Suzette Delaloge , Michael Gnant , Neelima Denduluri , Robert Separovic
Cancer Research
2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Manuel Ruiz-Borrego , Thomas Bachelot , Patrick Neven , Eva Ciruelos
Lancet Oncology 22 ( 4) 489 -498
123
2021